reports
Catalyst Pharmaceuticals Inc: 1 director
A director at Catalyst Pharmaceuticals Inc sold/sold after exercising options 26,746 shares at 23.253USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pu...
Catalyst Pharmaceuticals to Participate in the Bank of America CNS The...
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Bank of America CNS Therapeutics Virtual Conference on Mo...
- Jonathan Moreland
STAA STAAR SURGICAL CO.
MYE MYERS INDUSTRIES INC.
KVHI KVH INDUSTRIES INC.
GOGO GOGO INC.
GLP GLOBAL PARTNERS LP
FAST FASTENAL COMPANY
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
CNS COHEN & STEERS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
AP AMPCO-PITTSBURGH
KYN KAYNE ANDERSON MLP INVESTMENT CO.
ICHR ICHOR HOLDINGS LTD.
CELH CELSIUS HOLDINGS INC.
SONO SONOS
AEYE AUDIOEYE INC
AVTR AVANTOR
TELA INC.
UTZ TELA BIO
ACVA UTZ BRANDS INC (A)
NEXT ACV AUCTIONS INC.
EVLV NEXT CAPITAL
BHVN EVOLV TECHNOLOGIES HLDGS INC
VANI BIOHAVEN LTD
WEST VIVANI MEDICAL INC
SMRT WESTROCK COFFEE COMPANY LLC
GTE SMARTRENT INC
ET GRAN TIERRA ENERGY INC.
MNR ENERGY TRANSFER LP
CRVO MACH NATURAL RESOURCES LP
NCDL CERVOMED INC
SPRU NUVEEN CHURCHILL DIRECT LENDING CORP
MXF SPRUCE POWER HOLDING CORP
GF THE MEXICO FUND
HYMC INC.
BATRK THE NEW GERMANY FUND
GMRE INC.
ANNX HYCROFT MINING HOLDING CORPORATION
LIBERTY MEDIA CORP
GLOBAL MEDICAL REIT INC.
ANNEXIN PHARMACEUTICALS AB (PUBL)
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Co...
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 37th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at . About TELA Bio, In...
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-...
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™ Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced it ranked 304 on the ™, a ranking of the 500 fastest-growing tec...
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthca...
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in Citi’s 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 20...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
KVHI KVH INDUSTRIES INC.
GLP GLOBAL PARTNERS LP
FOXF FOX FACTORY HOLDING CORP.
FLDM FLUIDIGM
ALG ALAMO GROUP INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
TREX TREX COMPANY INC.
ICHR ICHOR HOLDINGS LTD.
CELH CELSIUS HOLDINGS INC.
HFFG HF FOODS GROUP INC
AVTR AVANTOR
PGNY INC.
TELA PROGYNY
SMCI TELA BIO
MRVI SUPER MICRO COMPUTER
BLND INC.
BHVN MARAVAI LIFESCIENCES HOLDINGS
DRCT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
VANI BIOHAVEN LTD
GTE DIRECT DIGITAL HLDGS INC
GT VIVANI MEDICAL INC
CRVO GRAN TIERRA ENERGY INC.
NCDL GOODYEAR TIRE & RUBBER CO.
NEXT CERVOMED INC
CATX NUVEEN CHURCHILL DIRECT LENDING CORP
RMI NEXTSOURCE MATERIALS INC.
BATRK PERSPECTIVE THERAPEUTICS
GMRE INC.
RIVERNORTH OPPOR MUN INC FD INC
LIBERTY MEDIA CORP
GLOBAL MEDICAL REIT INC.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a gra...
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Di...
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 7,523,000 shares of common stock at an offering p...
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing ...
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highli...
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results ...
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence in Long-term Outlook Conference Call and Webcast to be Held on Thursday, November 6, 2025, at 8:30 AM E...
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to...
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named as one of the BioSpace 2026 Best Places to Work for the second consecutive year, ranking 13 among 30 U.S. employers in the small company category. "We are honored to be na...
TELA Bio to Announce Third Quarter 2025 Financial Results
TELA Bio to Announce Third Quarter 2025 Financial Results MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInve...
TELA Bio Appoints William Plovanic to Board of Directors
TELA Bio Appoints William Plovanic to Board of Directors MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William (“Bill”) Plovanic, CFA, to its Board of Directors. Mr. Plovanic brings a distinctive combination of capital markets expertise and operational leadership in medical technology. He currently serves as Managing Director, Healthcare Equity ...
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare...
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, 2...
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Result...
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2025 financial results after the market c...
TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors ...
TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board. Dr. Rocchio is a nationally recognized healthcare leader and ...
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientifi...
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that data developed by or in conjunction with the company will be presented at several upcoming scientific conferences, details of which are listed below. "At Catalyst, everything begins with patients. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.